<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01240525</url>
  </required_header>
  <id_info>
    <org_study_id>UCL/10/0241</org_study_id>
    <secondary_id>UCL-10/0241</secondary_id>
    <secondary_id>LRF-09041</secondary_id>
    <secondary_id>EU-21081</secondary_id>
    <secondary_id>CRUK-UCL-PROT4</secondary_id>
    <nct_id>NCT01240525</nct_id>
  </id_info>
  <brief_title>Donor Lymphocyte Infusion After Stem Cell Transplant in Treating Patients With Haematological Cancers</brief_title>
  <acronym>ProT4</acronym>
  <official_title>Multicenter Randomized Phase II Study to Evaluate the Efficacy of Prophylactic Transfer of CD4 Lymphocytes After T-cell Depleted Reduced Intensity HLA-Identical Sibling Transplantation for Haematological Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving low doses of chemotherapy, such as fludarabine and melphalan, before a
      donor stem cell transplant helps stop the growth of cancer cells. It also stops the patient's
      immune system from rejecting the donor's stem cells. The donated stem cells may replace the
      patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor
      effect). Giving an infusion of the donor's T cells (donor lymphocyte infusion) that have been
      treated in the laboratory after the transplant may help increase this effect. Sometimes the
      transplanted cells from a donor can also make an immune response against the body's normal
      cells. Giving alemtuzumab before transplant and cyclosporine after transplant, may stop this
      from happening.

      PURPOSE: This randomized phase II trial is studying donor lymphocyte infusion after stem cell
      transplant in preventing cancer relapse or cancer progression in patients with follicular
      lymphoma, small lymphocytic non-Hodgkin lymphoma, or chronic lymphocytic leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To evaluate the effect of prophylactic transfer of donor CD4 cells after T-cell depleted
           reduced-intensity HLA-identical sibling transplantation upon the risk of relapse or
           progression in patients with haematological cancers (e.g. NHL, HL, CLL/PLL, PCM, AML,
           ALL, MDS or CMML depending on the disease status).

      Secondary

        -  To evaluate the effect of prophylactic transfer of donor CD4 cells upon the risk of
           graft-versus-host disease (GvHD) in these patients.

        -  To evaluate the effect of prophylactic transfer of donor CD4 cells upon the rates of
           conversion to full donor chimerism in peripheral blood in these patients.

        -  To determine the effect of prophylactic transfer of donor CD4 cells upon immune
           reconstitution in these patients.

        -  To evaluate the impact of prophylactic transfer of donor CD4 cells upon non-relapse
           mortality and overall survival of these patients.

      OUTLINE: This is a multicenter study.

      Patients receive fludarabine IV, melphalan IV, and alemtuzumab IV as reduced intensity
      conditioning for T-cell depletion followed by a reduced-intensity HLA-identical sibling stem
      cell transplantation on day 0. Withdrawal of cyclosporine immunosuppression therapy commence
      at day 40 with tapering over a period of 3-4 weeks, according to the discretion of the PI.
      Patients are reassessed between day 70-90 post-transplantation. Patients with stable
      engraftment, no significant graft-versus-host disease, and no early relapse or progression
      are randomized to 1 of 2 treatment arms.

        -  Arm I: Patients receive an allogeneic CD4 donor lymphocyte infusion (DLI) at a dose of 1
           x10^6 CD4 cells/kg body weight without any other medication once between day 100-120.

        -  Arm II: Patients receive no further treatment.

      Patients undergo blood sample collection for chimerism studies and translational research.

      After completion of study treatment, patients are followed up periodically for 1 years and
      then annually.

      Peer Reviewed and Funded or Endorsed by Bloodwise.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2011</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival at 1 year post-transplant</measure>
    <time_frame>during the study and end of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients attaining multi-lineage full donor chimerism in peripheral blood</measure>
    <time_frame>End of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of infection requiring inpatient treatment</measure>
    <time_frame>during the study and end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of reconstitution of T-cell subsets and viral-specific immunity</measure>
    <time_frame>End of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of non-relapse mortality at 1 year</measure>
    <time_frame>End of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival and non-relapse mortality</measure>
    <time_frame>End of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence, grade, or pattern of graft-versus-host disease</measure>
    <time_frame>during the study and end of study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Graft Versus Host Disease</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Myeloma</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>CD4 DLI</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will receive trial product manipulated CD4 DLI post transplant as trial treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No DLI</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will receive no DLI post transplant as trial treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CD4 DLI</intervention_name>
    <description>Patients will receive CD4 DLI between day 70 to 115 post transplant</description>
    <arm_group_label>CD4 DLI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No DLI</intervention_name>
    <description>Patients will not receive DLI as trial treatment</description>
    <arm_group_label>No DLI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        At registration (pre-transplant)

          -  Haematological cancer which can be ONE OF the following:

               -  Non-Hodgkin's lymphoma (NHL) in CR or PR

               -  Hodgkin's lymphoma (HL) in CR or PR

               -  Chronic (Pro-)lymphocytic leukaemia (CLL/PLL) in CR or PR

               -  Plasma cell myeloma (PCM) in CR, VGPR or PR

               -  Acute myeloid leukaemia (AML) in CR

               -  Acute lymphoblastic leukaemia (ALL) in CR

               -  Myelodysplastic syndrome (MDS) &lt; 10% blasts in bone marrow

               -  Chronic myelomonocytic leukaemia (CMML) &lt; 10% blasts in bone marrow

          -  Have undergone disease reassessment within 8 weeks prior to registration

          -  HLA-identical sibling transplant to be performed using one of the following reduced
             intensity alemtuzumab-containing conditioning regimens:

               -  Fludarabine-busulphan-alemtuzumab

               -  Fludarabine-melphalan-alemtuzumab

               -  BCNU-etoposide-cytarabine-melphalan (BEAM)-alemtuzumab

               -  CCNU-etoposide-cytarabine-melphalan (LEAM)-alemtuzumab

          -  Aged ≥18 years, and &lt;70 years

          -  Written informed consent

        Exclusion Criteria

          -  Women who are pregnant or breast-feeding

          -  Life expectancy of &lt;8 weeks

          -  Currently taking part in any other interventional clinical research study (involving
             any IMP, ATMP or cellular therapy)

          -  Organ dysfunction: Creatinine &gt;200μmol/l, Bilirubin &gt;50μmol/l, or AST/ALT &gt; 3x ULN

        Post-transplant

          -  Active acute GvHD

          -  Prior grade II-IV GvHD

          -  Relapse or progressive disease

          -  Primary or secondary graft failure

          -  Other cellular therapies

          -  Requirement for ongoing immunosuppression
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronjon Chakraverty, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University College Hospital London; UCL Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ka Man Condne, BSc, MSc</last_name>
    <phone>02076799427</phone>
    <email>ctc.prot4@ucl.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Haematology Trials Group</last_name>
    <phone>02076799860</phone>
    <email>ctc.bnli@ucl.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Birmingham Heartlands Hospital</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Richard Lovell, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bristol Royal Hospital for Children</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stephen Robinson, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ben Uttenthal, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andrew Clark, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Maria Gilleece, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ann Hunter, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College Hospital London (UCLH)</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>r.chakraverty@ucl.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Ronjon Chakraverty, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christie Hospital</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Adrian Bloor, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nottingham City Hospital</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nigel Russell, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Hallamshire Hospital</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>John Snowden, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Southampton</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Debbie Richardson, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.ctc.ucl.ac.uk/TrialDetails.aspx?TrialID=54</url>
    <description>CRUK &amp; UCL Cancer Trial Centre - coordinating centre</description>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2010</study_first_submitted>
  <study_first_submitted_qc>November 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2010</study_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>graft versus host disease</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>Waldenstrom macroglobulinemia</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>Non-Hodgkin's lymphoma</keyword>
  <keyword>Hodgkin's lymphoma</keyword>
  <keyword>Chronic (Pro-)lymphocytic leukaemia</keyword>
  <keyword>Plasma cell myeloma</keyword>
  <keyword>Acute myeloid leukaemia</keyword>
  <keyword>Acute lymphoblastic leukaemia</keyword>
  <keyword>Myelodysplastic syndrome</keyword>
  <keyword>Chronic myelomonocytic leukaemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

